ABSCINT
A clinical stage molecular imaging company developing in-vivo diagnostics based on single domain antibodies.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
* | €3.0m | Early VC | |
| Total Funding | 000k | ||
| EUR | 2021 | 2022 | 2023 |
|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Abscint is a healthcare company dedicated to improving patient lives by providing access to accurate and timely diagnostic solutions. Operating in the medical diagnostics market, Abscint serves healthcare providers and patients who require precise disease detection to manage and treat health conditions effectively. The company's business model revolves around developing and offering advanced diagnostic tools that enable early disease detection, which is crucial for preventing disease progression and ensuring appropriate clinical management. Abscint generates revenue through the sale of its diagnostic products and services to medical institutions and healthcare professionals. By leveraging a multidisciplinary team of experts, Abscint aims to deliver innovative solutions that enhance patient outcomes and contribute to longer, healthier lives.
Keywords: diagnostic solutions, patient outcomes, disease detection, healthcare, medical diagnostics, early detection, clinical management, healthcare providers, multidisciplinary team, innovative solutions.